Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
SAGA Metals Reports Assays from R-0018 to R-0020 with Intercepts Including 49.51% Fe?O?, 6.56% TiO?, 0.374% V?O? from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
